Small molecular inhibitors: Therapeutic strategies for pancreatic cancer
Recommended Citation
Golivi Y, Kumari S, Farran B, Alam A, Peela S, and Nagaraju GP. Small molecular inhibitors: Therapeutic strategies for pancreatic cancer. Drug Discov Today 2024; 29(7):104053.
Document Type
Article
Publication Date
7-1-2024
Publication Title
Drug discovery today
Abstract
Pancreatic cancer (PC), a disease with high heterogeneity and a dense stromal microenvironment, presents significant challenges and a bleak prognosis. Recent breakthroughs have illuminated the crucial interplay among RAS, epidermal growth factor receptor (EGFR), and hedgehog pathways in PC progression. Small molecular inhibitors have emerged as a potential solution with their advantages of oral administration and the ability to target intracellular and extracellular sites effectively. However, despite the US FDA approving over 100 small-molecule targeted antitumor drugs, challenges such as low response rates and drug resistance persist. This review delves into the possibility of using small molecules to treat persistent or spreading PC, highlighting the challenges and the urgent need for a diverse selection of inhibitors to develop more effective treatment strategies.
Medical Subject Headings
Humans; Pancreatic Neoplasms; Antineoplastic Agents; Animals; Drug Resistance, Neoplasm; Molecular Targeted Therapy; ErbB Receptors; Hedgehog Proteins; Small Molecule Libraries
PubMed ID
38849028
Volume
29
Issue
7
First Page
104053
Last Page
104053
